300294 博雅生物
已收盘 04-24 15:00:00
资讯
新帖
简况
博雅生物(300294)4月10日股东户数3.23万户,较上期减少0.95%
证券之星 · 17:12
博雅生物(300294)4月10日股东户数3.23万户,较上期减少0.95%
图解博雅生物一季报:第一季度单季净利润同比下降78.33%
证券之星 · 03:17
图解博雅生物一季报:第一季度单季净利润同比下降78.33%
华润医药旗下博雅生物季度营收32.11亿元 净利润达3000万元
美股速递 · 04-24 20:19
华润医药旗下博雅生物季度营收32.11亿元 净利润达3000万元
博雅生物:公司产品暂未进行出口捐赠
证券之星 · 04-24 17:06
博雅生物:公司产品暂未进行出口捐赠
博雅生物(300294)3月31日股东户数3.23万户,较上期减少0.75%
证券之星 · 04-16
博雅生物(300294)3月31日股东户数3.23万户,较上期减少0.75%
股市必读:博雅生物(300294)4月2日董秘有最新回复
证券之星 · 04-03
股市必读:博雅生物(300294)4月2日董秘有最新回复
博雅生物:公司2026年3月31日含信用账户合并名册的股东人数为32,561户
证券之星 · 04-02
博雅生物:公司2026年3月31日含信用账户合并名册的股东人数为32,561户
股市必读:博雅生物(300294)3月27日董秘有最新回复
证券之星 · 03-30
股市必读:博雅生物(300294)3月27日董秘有最新回复
博雅生物:固定资产与无形资产的增值部分则在其各自的剩余使用寿命内,通过折旧与摊销方式逐年计入费用
证券之星 · 03-24
博雅生物:固定资产与无形资产的增值部分则在其各自的剩余使用寿命内,通过折旧与摊销方式逐年计入费用
博雅生物:2025年利润下滑主要由于安徽格林克代理经销的医美产品玻尿酸市场下行
证券之星 · 03-24
博雅生物:2025年利润下滑主要由于安徽格林克代理经销的医美产品玻尿酸市场下行
华润医药(03320):华润博雅生物2025年归母净利润约1.13亿元 同比减少71.61%
智通财经 · 03-20
华润医药(03320):华润博雅生物2025年归母净利润约1.13亿元 同比减少71.61%
博雅生物(300294.SZ)发布2025年度业绩,归母净利润1.13亿元,下降71.61%
智通财经 · 03-20
博雅生物(300294.SZ)发布2025年度业绩,归母净利润1.13亿元,下降71.61%
博雅生物:坚持长期主义,聚焦主业,强化核心竞争力
证券之星 · 03-20
博雅生物:坚持长期主义,聚焦主业,强化核心竞争力
股市必读:博雅生物(300294)3月13日董秘有最新回复
证券之星 · 03-16
股市必读:博雅生物(300294)3月13日董秘有最新回复
博雅生物:成为世界一流血液制品企业
证券之星 · 03-13
博雅生物:成为世界一流血液制品企业
股市必读:博雅生物(300294)3月6日董秘有最新回复
证券之星 · 03-09
股市必读:博雅生物(300294)3月6日董秘有最新回复
博雅生物:我国对血液制品的进口采取严格的管制措施
证券之星 · 03-06
博雅生物:我国对血液制品的进口采取严格的管制措施
博雅生物:公司二级市场股票价格受到宏观环境、行业政策、投资者风险偏好等因素影响
证券之星 · 03-06
博雅生物:公司二级市场股票价格受到宏观环境、行业政策、投资者风险偏好等因素影响
股市必读:博雅生物(300294)3月2日董秘有最新回复
证券之星 · 03-03
股市必读:博雅生物(300294)3月2日董秘有最新回复
博雅生物:公司2026年2月27日含信用账户合并名册的股东人数为31,746户
证券之星 · 03-02
博雅生物:公司2026年2月27日含信用账户合并名册的股东人数为31,746户
加载更多
公司概况
公司名称:
华润博雅生物制药集团股份有限公司
所属行业:
医药制造业
上市日期:
2012-03-08
主营业务:
华润博雅生物制药集团股份有限公司的主营业务是血液制品的研发、生产和销售。公司的主要产品是人血白蛋白、人免疫球蛋白、静注人免疫球蛋白(含10%高浓度剂型)、冻干静注人免疫球蛋白、乙肝人免疫球蛋白、破伤风免疫球蛋白、狂犬病人免疫球蛋白、人纤维蛋白原、人凝血酶原复合物、人凝血因子Ⅷ。公司技术实力雄厚,先后承担了国家“863计划”项目、江西省重大研发专项等20多项政府专项,拥有各类专利200余项,多次荣膺省、市科学技术奖和优秀新产品奖。
发行价格:
25.00
{"stockData":{"symbol":"300294","market":"SZ","secType":"STK","nameCN":"博雅生物","latestPrice":18.55,"timestamp":1777014213000,"preClose":18.56,"halted":0,"volume":3435600,"delay":0,"changeRate":-0.0005,"floatShares":504000000,"shares":504000000,"eps":-0.3403,"marketStatus":"已收盘","change":-0.01,"latestTime":"04-24 15:00:00","open":18.5,"high":18.56,"low":18.28,"amount":63359100,"amplitude":0.0151,"askPrice":18.55,"askSize":181,"bidPrice":18.53,"bidSize":38,"shortable":0,"etf":0,"ttmEps":-0.3403,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1777253400000},"marketStatusCode":5,"adr":0,"adjPreClose":18.56,"symbolType":"stock","openAndCloseTimeList":[[1776994200000,1777001400000],[1777006800000,1777014000000]],"highLimit":20.42,"lowLimit":16.7,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":504248738,"isCdr":false,"pbRate":1.26,"roa":"--","roe":"1.51%","epsLYR":0.22,"committee":-0.190525,"marketValue":9354000000,"turnoverRate":0.0068,"status":1,"floatMarketCap":9354000000},"requestUrl":"/m/hq/s/300294","defaultTab":"news","newsList":[{"id":"2630870696","title":"博雅生物(300294)4月10日股东户数3.23万户,较上期减少0.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630870696","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630870696?lang=zh_cn&edition=full","pubTime":"2026-04-25 17:12","pubTimestamp":1777108326,"startTime":"0","endTime":"0","summary":"证券之星消息,近日博雅生物披露,截至2026年4月10日公司股东户数为3.23万户,较3月31日减少308.0户,减幅为0.95%。在生物制品行业个股中,博雅生物股东户数低于行业平均水平,截至4月10日,生物制品行业平均股东户数为3.6万户。从股价来看,2026年3月31日至2026年4月10日,博雅生物区间涨幅为1.56%,在此期间股东户数减少308.0户,减幅为0.95%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500032648.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300294","BK0239","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630824728","title":"图解博雅生物一季报:第一季度单季净利润同比下降78.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630824728","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630824728?lang=zh_cn&edition=full","pubTime":"2026-04-25 03:17","pubTimestamp":1777058238,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物2026年一季报显示,一季度公司主营收入3.21亿元,同比下降40.07%;归母净利润3022.09万元,同比下降78.33%;扣非净利润2032.35万元,同比下降80.13%;负债率11.22%,投资收益393.33万元,财务费用-1006.81万元,毛利率46.26%。财报数据概要请见下图:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042500008999.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186809146","title":"华润医药旗下博雅生物季度营收32.11亿元 净利润达3000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1186809146","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186809146?lang=zh_cn&edition=full","pubTime":"2026-04-24 20:19","pubTimestamp":1777033154,"startTime":"0","endTime":"0","summary":"华润医药集团旗下控股子公司博雅生物最新季度财务数据显示,公司实现未经审计营业收入32.11亿元人民币,净利润录得3000万元。作为血液制品行业的领军企业,博雅生物本季度业绩展现出稳健的经营态势。\n从财务结构来看,公司营收规模保持较高水平,净利润表现符合市场预期。在医药行业政策持续优化的背景下,博雅生物通过精细化管理和技术创新,持续巩固其在血液制品领域的技术优势和市场地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0046","03320","BK1570","BK0197","300294","BK1191","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629811681","title":"博雅生物:公司产品暂未进行出口捐赠","url":"https://stock-news.laohu8.com/highlight/detail?id=2629811681","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629811681?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:06","pubTimestamp":1777021566,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物04月24日在投资者关系平台上答复投资者关心的问题。公司股价连跌了一年半,为国资保值增值,公司有否计划对市值进行目标管理?公司产品暂未进行出口捐赠。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400051243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0197","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627295595","title":"博雅生物(300294)3月31日股东户数3.23万户,较上期减少0.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627295595","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627295595?lang=zh_cn&edition=full","pubTime":"2026-04-16 17:13","pubTimestamp":1776330826,"startTime":"0","endTime":"0","summary":"证券之星消息,近日博雅生物披露,截至2026年3月31日公司股东户数为3.23万户,较3月20日减少244.0户,减幅为0.75%。在生物制品行业个股中,博雅生物股东户数低于行业平均水平,截至3月31日,生物制品行业平均股东户数为3.5万户。从股价来看,2026年3月20日至2026年3月31日,博雅生物区间跌幅为4.97%,在此期间股东户数减少244.0户,减幅为0.75%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041600030830.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","300294","BK0046","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624689362","title":"股市必读:博雅生物(300294)4月2日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2624689362","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624689362?lang=zh_cn&edition=full","pubTime":"2026-04-03 01:56","pubTimestamp":1775152573,"startTime":"0","endTime":"0","summary":"截至2026年4月2日收盘,博雅生物报收于19.11元,下跌0.05%,换手率1.03%,成交量5.18万手,成交额9869.89万元。董秘最新回复投资者: 请问公司董事长在华润医药担任什么职务?经查询中国证券登记结算有限责任公司的数据,公司2026年3月31日含信用账户合并名册的股东人数为32,561户。当日关注点来自交易信息汇总:4月2日主力资金净流入480.62万元,散户资金净流出519.07万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300001639.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0197","BK0239","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624051505","title":"博雅生物:公司2026年3月31日含信用账户合并名册的股东人数为32,561户","url":"https://stock-news.laohu8.com/highlight/detail?id=2624051505","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624051505?lang=zh_cn&edition=full","pubTime":"2026-04-02 19:36","pubTimestamp":1775129766,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)04月02日在投资者关系平台上答复投资者关心的问题。投资者提问:请问截止到2026年3月31日,股东人数是多少?博雅生物回复:您好,感谢您对本公司的关注。经查询中国证券登记结算有限责任公司的数据,公司2026年3月31日含信用账户合并名册的股东人数为32,561户。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200036067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0239","BK0046","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623633393","title":"股市必读:博雅生物(300294)3月27日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2623633393","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623633393?lang=zh_cn&edition=full","pubTime":"2026-03-30 05:33","pubTimestamp":1774819991,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘,博雅生物报收于18.85元,上涨1.84%,换手率0.96%,成交量4.84万手,成交额9054.0万元。公司对外投资均严格履行相关决策程序。经查询中国证券登记结算有限责任公司的数据,公司2026年3月20日含信用账户合并名册的股东人数为32,497户。当日关注点来自交易信息汇总:3月27日主力资金净流出235.6万元,显示主力对博雅生物短期态度偏谨慎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000001191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","300294","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621050461","title":"博雅生物:固定资产与无形资产的增值部分则在其各自的剩余使用寿命内,通过折旧与摊销方式逐年计入费用","url":"https://stock-news.laohu8.com/highlight/detail?id=2621050461","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621050461?lang=zh_cn&edition=full","pubTime":"2026-03-24 17:09","pubTimestamp":1774343365,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)03月24日在投资者关系平台上答复投资者关心的问题。投资者提问:请问公司并购绿十字产生的增值摊销还有多少,预计需要摊销多少年。博雅生物回复:您好,感谢您对本公司的关注。公司收购绿十字形成的资产增值主要涉及固定资产、无形资产及存货。其中,评估增值的存货在实现销售时相应结转成本;固定资产与无形资产的增值部分,则在其各自的剩余使用寿命内,通过折旧与摊销方式逐年计入费用。相关详情请关注定期报告附注。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400028406.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","300294","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621050432","title":"博雅生物:2025年利润下滑主要由于安徽格林克代理经销的医美产品玻尿酸市场下行","url":"https://stock-news.laohu8.com/highlight/detail?id=2621050432","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621050432?lang=zh_cn&edition=full","pubTime":"2026-03-24 17:09","pubTimestamp":1774343363,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物03月24日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好,公司2024年、2025年连续两年均呈现下半年营收、营业利润、净利润低于上半年的情况。2025年利润下滑主要由于安徽格林克代理经销的医美产品玻尿酸市场下行,产生无形资产减值1.97亿元人民币、商誉减值1.10亿元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400028397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","300294","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620017738","title":"华润医药(03320):华润博雅生物2025年归母净利润约1.13亿元 同比减少71.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620017738","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620017738?lang=zh_cn&edition=full","pubTime":"2026-03-20 19:44","pubTimestamp":1774007095,"startTime":"0","endTime":"0","summary":"智通财经APP讯,华润医药(03320)公布华润博雅生物2025年业绩,营业总收入约20.59亿元,同比增长18.69%;上市公司股东应占净利润约1.13亿元,同比减少71.61%;每股基本盈利0.22元,拟每10股派现金股息0.73元( 含税)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416759.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300294","03320"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620738155","title":"博雅生物(300294.SZ)发布2025年度业绩,归母净利润1.13亿元,下降71.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620738155","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620738155?lang=zh_cn&edition=full","pubTime":"2026-03-20 19:27","pubTimestamp":1774006071,"startTime":"0","endTime":"0","summary":"智通财经APP讯,博雅生物(300294.SZ)发布2025年年度报告,该公司营业收入为20.59亿元,同比增长18.69%。归属于上市公司股东的净利润为1.13亿元,同比减少71.61%。归属于上市公司股东的扣除非经常性损益的净亏损为775.75万元。基本每股收益为0.22元。此外,拟向全体股东每10股派发现金红利0.73元(含税)。报告期,格林克产品市场下行,导致无形资产和商誉减值损失增加,以及并购绿十字产生的评估增值摊销增加影响,另外血制品业务受集采、DRG/DIP改革、医保控费、市场竞争加剧等因素影响毛利率同比下降。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620782640","title":"博雅生物:坚持长期主义,聚焦主业,强化核心竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2620782640","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620782640?lang=zh_cn&edition=full","pubTime":"2026-03-20 18:03","pubTimestamp":1774000994,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)03月20日在投资者关系平台上答复投资者关心的问题。投资者提问:近日来,股价连续刷新10年新低,请问企业及控股股东是否有什么对策博雅生物回复:您好,感谢您对本公司的关注。公司二级市场股票价格受到宏观环境、行业政策、投资者风险偏好等因素影响。公司一直坚持长期主义,紧紧围绕战略目标,聚焦主业,强化核心竞争力,结合政策环境、市场环境等制定适合公司发展的经营策略,努力做好经营管理,提升经营质量与盈利能力,促进公司健康可持续发展。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000033534.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","300294","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619048876","title":"股市必读:博雅生物(300294)3月13日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2619048876","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619048876?lang=zh_cn&edition=full","pubTime":"2026-03-16 03:28","pubTimestamp":1773602893,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘,博雅生物报收于20.85元,上涨0.05%,换手率0.85%,成交量4.3万手,成交额9006.25万元。投资者: 您好,请问截止3月10日股东人数是多少董秘: 您好,感谢您对本公司的关注。公司2026年3月10日含信用账户合并名册的股东人数为32,507户。公司股价已创近10年新低,且大幅跑输血制品板块。控股股东华润曾于2025年5月完成增持,此后暂无新的安排。公司二级市场股票价格受到宏观环境、行业政策、投资者风险偏好等因素影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600001323.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0197","BK0239","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619160616","title":"博雅生物:成为世界一流血液制品企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2619160616","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619160616?lang=zh_cn&edition=full","pubTime":"2026-03-13 17:12","pubTimestamp":1773393130,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物03月13日在投资者关系平台上答复投资者关心的问题。公司生产经营情况稳定,具体经营情况及财务状况请参阅公司公告。华润博雅生物围绕“成为世界一流血液制品企业”的战略目标,在复杂多变的市场环境中攻坚克难,立足血浆拓展、终端掌控、研发创新、国际化等方向持续发力,提升公司综合竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300028939.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0046","BK0239","300294"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618769377","title":"股市必读:博雅生物(300294)3月6日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2618769377","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618769377?lang=zh_cn&edition=full","pubTime":"2026-03-09 01:19","pubTimestamp":1772990349,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘,博雅生物报收于21.21元,上涨2.81%,换手率1.39%,成交量7.01万手,成交额1.47亿元。董秘最新回复投资者: 请问贵公司是否承接国家战略储备和应急调拨等方面的业务。投资者: 你好董秘,大盘自2024年10.8号以来累积涨幅已达20%,贵公司对投资者回复中一直表示生产经营正常,没有重大影响,但股价却从2024年10.8号以来跌幅深度达到接近50%。截至目前,中东局势对公司无直接关联的影响。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030900000576.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300294","BK0046","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617685940","title":"博雅生物:我国对血液制品的进口采取严格的管制措施","url":"https://stock-news.laohu8.com/highlight/detail?id=2617685940","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617685940?lang=zh_cn&edition=full","pubTime":"2026-03-06 17:00","pubTimestamp":1772787637,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物03月06日在投资者关系平台上答复投资者关心的问题。谢谢博雅生物回复:您好,感谢您对本公司的关注。鉴于血液制品的特殊性和安全性,我国对血液制品的进口采取严格的管制措施,1985年开始国家禁止除人血白蛋白以外的血液制品的进口,2002年起禁止从疯牛病疫区进口人血白蛋白。产品价格受市场供需关系影响,公司根据市场环境变化制定相应的价格策略。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600026960.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","BK0239","300294","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617903685","title":"博雅生物:公司二级市场股票价格受到宏观环境、行业政策、投资者风险偏好等因素影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2617903685","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617903685?lang=zh_cn&edition=full","pubTime":"2026-03-06 17:00","pubTimestamp":1772787636,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物03月06日在投资者关系平台上答复投资者关心的问题。贵公司正常经营的情况下股价为何与大盘走势反其道而行之?广大中小投资人对此保留诉讼权利。公司二级市场股票价格受到宏观环境、行业政策、投资者风险偏好等因素影响。公司经营情况及财务状况请参阅公司公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600026958.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","300294","BK0197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616357927","title":"股市必读:博雅生物(300294)3月2日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2616357927","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616357927?lang=zh_cn&edition=full","pubTime":"2026-03-03 01:40","pubTimestamp":1772473222,"startTime":"0","endTime":"0","summary":"截至2026年3月2日收盘,博雅生物报收于21.85元,下跌1.8%,换手率0.99%,成交量4.98万手,成交额1.09亿元。董秘最新回复投资者: 请问,截至2月27日,公司股东账户数量多少?公司2026年2月27日含信用账户合并名册的股东人数为31,746户。近期管理层出现人事调整,作为长期股东,十分关注公司经营连续性与战略稳定性。当日关注点来自交易信息汇总:3月2日主力资金净流出1448.9万元,显示主力短期看空情绪明显。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300000930.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300294","BK0046","BK0197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616387837","title":"博雅生物:公司2026年2月27日含信用账户合并名册的股东人数为31,746户","url":"https://stock-news.laohu8.com/highlight/detail?id=2616387837","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616387837?lang=zh_cn&edition=full","pubTime":"2026-03-02 17:21","pubTimestamp":1772443277,"startTime":"0","endTime":"0","summary":"证券之星消息,博雅生物(300294)03月02日在投资者关系平台上答复投资者关心的问题。投资者提问:请问,截至2月27日,公司股东账户数量多少?谢谢!博雅生物回复:您好,感谢您对本公司的关注。公司2026年2月27日含信用账户合并名册的股东人数为31,746户。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200024742.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0197","BK0239","300294"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777130811381,"stockEarnings":[{"period":"1week","weight":-0.0154},{"period":"1month","weight":-0.0133},{"period":"3month","weight":-0.1994},{"period":"6month","weight":-0.2499},{"period":"1year","weight":-0.3172},{"period":"ytd","weight":-0.1792}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":0.0377},{"period":"3month","weight":-0.0136},{"period":"6month","weight":0.0328},{"period":"1year","weight":0.2374},{"period":"ytd","weight":0.028}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华润博雅生物制药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"32253人(较上一季度减少0.95%)","perCapita":"15634股","listingDate":"2012-03-08","address":"江西省抚州市临川区高新技术产业开发区惠泉路333号","registeredCapital":"50424万元","survey":" 华润博雅生物制药集团股份有限公司的主营业务是血液制品的研发、生产和销售。公司的主要产品是人血白蛋白、人免疫球蛋白、静注人免疫球蛋白(含10%高浓度剂型)、冻干静注人免疫球蛋白、乙肝人免疫球蛋白、破伤风免疫球蛋白、狂犬病人免疫球蛋白、人纤维蛋白原、人凝血酶原复合物、人凝血因子Ⅷ。公司技术实力雄厚,先后承担了国家“863计划”项目、江西省重大研发专项等20多项政府专项,拥有各类专利200余项,多次荣膺省、市科学技术奖和优秀新产品奖。","listedPrice":25},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博雅生物,300294,博雅生物股票,博雅生物股票老虎,博雅生物股票老虎国际,博雅生物行情,博雅生物股票行情,博雅生物股价,博雅生物股市,博雅生物股票价格,博雅生物股票交易,博雅生物股票购买,博雅生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博雅生物(300294)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博雅生物(300294)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}